Financial Data and Key Metrics Changes - Forian reported consolidated revenue of $1.6 million for Q1 2021, an increase of over $1.5 million compared to the prior year, driven by the inclusion of Helix results and year-over-year growth in the company's products [20][21] - On a pro forma basis, revenue was $3.8 million, growing 22% year-over-year, primarily driven by the information and software segment, which grew 26% [21] - Loss from operations widened by $4.4 million year-over-year to $5.1 million, primarily due to investments in product development and customer service [21][22] Business Line Data and Key Metrics Changes - The information and software revenue segment includes BioTrack and Cannalytics software solutions, contributing significantly to revenue growth [20] - The services segment includes government traceability and real-world evidence solutions, which are critical as legalization continues [20][21] Market Data and Key Metrics Changes - The legal cannabis market is expected to grow at an estimated 20% compounded annual growth rate, indicating a rapidly expanding market for Forian's services [8] - The company noted that customer interest in its information product offerings is growing, providing confidence in revenue opportunities [23] Company Strategy and Development Direction - Forian aims to be a trusted source of technology and analytics for the cannabis market while also serving traditional healthcare companies [4][5] - Key priorities for 2021 include developing innovative products, delivering exceptional service, ensuring operational improvements, and attracting top talent [17] - The company is focused on enhancing its product offerings, particularly BioTrack and Cannalytics, to drive business performance improvements [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to pre-COVID sales trajectories as the impact of the pandemic declines, with a positive outlook on customer buying patterns [27] - The company is not providing forward-looking guidance but is optimistic about its growing pipeline and larger contracts in the healthcare segment [23][30] Other Important Information - Forian completed the business combination of Helix and MOR Analytics on March 2, 2021, which is expected to enhance its market position [19] - The company raised $12 million of incremental capital just after the quarter concluded, strengthening its balance sheet [23] Q&A Session Summary Question: How does the company estimate growth prospects for the next year and into the future? - Management indicated that while they are not providing forward-looking guidance, they are seeing a growing pipeline and larger contracts in the healthcare segment, which supports their growth outlook [30] Question: How is COVID affecting Forian? - Management noted that as COVID-19's impact declines, they expect sales and operations to revert to pre-COVID trajectories, with a return to normal customer buying patterns [27]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charter) Delaware 85-3467693 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Identifi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charter) Delaware 85-3467693 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Iden ...

Financial Data and Key Metrics Changes - In Q2 2019, the company generated revenues of $3.9 million, an increase of 108% compared to $1.87 million in the prior year [19] - Gross profit for Q2 was $1.9 million, up from $314,000 in Q2 2018, resulting in a gross margin of 49% compared to 17% in the prior year [19] - For the first half of 2019, revenues reached $7.27 million, a 142% increase from $3 million in the first half of 2018, with a gross margin of 46% [20][21] Business Line Data and Key Metrics Changes - The software segment (BioTrack) generated revenues of $2.3 million in Q2 2019, reflecting 11% sequential growth and 44% year-over-year growth from $1.65 million in Q2 2018 [22][23] - The security guarding and monitoring business reported revenues of $1.52 million in Q2 2019, up 17% from $1.3 million in Q2 2018, with a gross margin of 25% [24] Market Data and Key Metrics Changes - The company added nearly 500 new software licenses, indicating strong growth in the software-as-a-service model [14] - The company has expanded its international footprint into the United Kingdom, enhancing its market presence in Europe [16] Company Strategy and Development Direction - The company focuses on generating cash flow from operations rather than solely relying on fundraising, aiming to create real value for investors [8][10] - The acquisition of Tan's International allows for rapid expansion in California operations, indicating a strategic move to enhance service capabilities [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational improvements and cash flow generation, which are critical for achieving strategic goals [10] - The company is addressing opportunities in the hemp sector, indicating a proactive approach to emerging market trends [27] Other Important Information - The company reported a loss from operations of $2.47 million in Q2 2019, slightly improved from a loss of $2.56 million in the prior year [19] - Cash flows from operations improved to negative $714,000 in Q2 2019 from negative $1.175 million in Q1 2019, showing a quarter-on-quarter improvement of over $450,000 [20] Q&A Session Summary Question: What is the company's stance on the hemp sector? - The company is actively addressing opportunities in the hemp sector and plans to make further announcements in this regard [27] Question: Are there any forward-looking statements that can be addressed? - The management indicated that many questions could not be addressed due to their forward-looking nature, concluding the live portion of the call [28]